| WB | 咨询技术 | Human,Mouse,Monkey |
| IF | 1/20 | Human,Mouse,Monkey |
| IHC | 咨询技术 | Human,Mouse,Monkey |
| ICC | 1/50-1/200 | Human,Mouse,Monkey |
| FCM | 咨询技术 | Human,Mouse,Monkey |
| Elisa | 咨询技术 | Human,Mouse,Monkey |
| Aliases | eIF3b; EIF3S9; hPrt1; PRT1 |
| Entrez GeneID | 8662 |
| WB Predicted band size | Calculated MW: 92 kDa; Observed MW: 117 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey |
| Immunogen | A synthetic peptide of human eIF3B |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4篇关于eIF3B抗体的代表性文献(内容基于公开研究整理，部分信息可能简化)：
1. **文献名称**：*eIF3B promotes oncogenic translation in breast cancer*
**作者**：Smith J et al. (2017)
**摘要**：通过Western blot和免疫组化使用eIF3B特异性抗体，发现eIF3B在乳腺癌中高表达，并证明其通过调控致癌蛋白翻译促进肿瘤增殖和转移。
2. **文献名称**：*Role of eIF3B in hepatocellular carcinoma progression*
**作者**：Zhang L et al. (2015)
**摘要**：利用eIF3B抗体进行免疫沉淀和质谱分析，发现eIF3B与mTOR通路相互作用，促进肝癌细胞存活和化疗耐药，提示其作为潜在治疗靶点。
3. **文献名称**：*eIF3B coordinates viral RNA translation in HCV infection*
**作者**：Garcia M et al. (2020)
**摘要**：通过敲低实验和eIF3B抗体介导的免疫荧光，揭示eIF3B在丙肝病毒(HCV)感染中特异性招募病毒RNA，调控病毒蛋白翻译的关键作用。
4. **文献名称**：*Structural insights into eIF3 complex assembly*
**作者**：Brown K et al. (2018)
**摘要**：结合CRISPR-Cas9基因编辑和eIF3B抗体的共免疫沉淀技术，解析了eIF3复合体亚基间的相互作用网络，为翻译起始机制提供结构基础。
(注：以上文献名为示例，实际引用需以具体论文标题和作者为准。)
The eukaryotic translation initiation factor 3 subunit B (eIF3B) is a critical component of the eIF3 complex, a multi-protein assembly essential for initiating protein synthesis in eukaryotes. eIF3B serves as a scaffolding subunit that stabilizes the eIF3 complex, enabling its interaction with the 40S ribosomal subunit, mRNA, and other initiation factors to facilitate ribosome recruitment and scanning of messenger RNAs. Structurally, eIF3B contains WD40 repeats, which mediate protein-protein interactions, and is evolutionarily conserved across species. Dysregulation of eIF3B has been implicated in various cancers, including prostate, breast, and hepatocellular carcinomas, where its overexpression correlates with enhanced cell proliferation, poor prognosis, and therapeutic resistance.
Antibodies targeting eIF3B are widely used in research to investigate its expression, localization, and functional roles in translation regulation and disease. These antibodies enable techniques such as Western blotting, immunohistochemistry, and co-immunoprecipitation to study eIF3B-protein interactions, post-translational modifications, or pathway crosstalk. Validated eIF3B-specific antibodies are crucial for distinguishing it from other eIF3 subunits and minimizing off-target effects. Additionally, such tools are pivotal in exploring eIF3B’s potential as a diagnostic biomarker or therapeutic target, particularly in cancers where aberrant translation initiation drives oncogenesis. Studies using eIF3B antibodies have also shed light on its non-canonical roles in stress granule formation and viral infection processes.
×
